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phagocytes in patients with HTLV-I associated
neurologic disease
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Abstract
Background: The activation of mononuclear phagocytes (MPs), including monocytes, macrophages and dendritic
cells, contributes to central nervous system inflammation in various neurological diseases. In HTLV-I-associated
myelopathy/tropical spastic paraparesis (HAM/TSP), MPs are reservoirs of HTLV-I, and induce proinflammatory
cytokines and excess T cell responses. The virus-infected or activated MPs may play a role in immuneregulation
and disease progression in patients with HTLV-I-associated neurological diseases.
Results: Phenotypic analysis of CD14+ monocytes in HAM/TSP patients demonstrated high expression of CX3CR1
and HLA-DR in CD14lowCD16+ monocytes, compared to healthy normal donors (NDs) and asymptomatic carriers
(ACs), and the production of TNF-a and IL-1b in cultured CD14+ cells of HAM/TSP patients. CD14+ cells of HAM/
TSP patients also showed acceleration of HTLV-I Tax expression in CD4+ T cells. Minocycline, an inhibitor of
activated MPs, decreased TNF-a expression in CD14+ cells and IL-1b release in PBMCs of HAM/TSP patients.
Minocycline significantly inhibited spontaneous lymphoproliferation and degranulation/IFN-g expression in CD8+
T cells of HAM/TSP patients. Treatment of minocycline also inhibited IFN-g expression in CD8+ T cells of HAM/TSP
patients after Tax11-19 stimulation and downregulated MHC class I expression in CD14+ cells.
Conclusion: These results demonstrate that minocycline directly inhibits the activated MPs and that the
downregulation of MP function can modulate CD8+ T cells function in HAM/TSP patients. It is suggested that
activated MPs may be a therapeutic target for clinical intervention in HAM/TSP.
Keywords: HTLV-I, HAM/TSP, monocyte, CTL, minocycline
Background
The human T cell lymphotropic virus I (HTLV-I) infects
20 million people worldwide of which the majority of
infected individuals are asymptomatic carriers (AC) of
the virus [1]. However, in a small percentage of infected
individuals, HTLV-I is the etiologic agent of adult T cell
leukemia/lymphoma (ATL) [2] and a chronic, progres-
sive neurological disease termed HTLV-I-associated
myelopathy/tropical spastic paraparesis (HAM/TSP)
[3,4]. Patients with HAM/TSP demonstrate high HTLV-
I proviral DNA load, high HTLV-I Tax mRNA load,
and high virus-specific immune responses, including
increased production of inflammatory cytokines and
expansion of Tax-specific CD8+ T cells [5-9]. A high
frequency of CD4+ T cells is persistently infected and
exhibits high expression of Tax protein [10]. These
infected cells are responsible for the increased lympho-
cyte proliferation in patients with HAM/TSP [11]. High
frequency of activated CD8+ T cells in peripheral blood
and even higher in cerebrospinal fluid has been reported
[12]. In addition to these strong HTLV-I-associated
T cell responses, it has been suggested that mononuc-
lear phagocytes (MPs; monocytes, dendritic cells, tissue
macrophages and microglia) are also involved in the
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pathogenesis of HAM/TSP. MPs are infected with
HTLV-I in vitro and in vivo [13-18], and dendritic cells
have been shown to effectively transfer cell-free virus to
CD4+ T cells [18]. HTLV-I-infected dendritic cells can
stimulate both CD4+ and CD8+ T cells [17]. Moreover,
HTLV-I infection of CD14+ cells and the concomitant
expression of IL-15 mediate spontaneous degranulation
and IFN-g expression in CD8+ T cells [19]. Pathological
studies have confirmed the presence of inflammatory
monocyte/macrophages as well as CD4+ T cells and
CD8+ T cells in the central nervous system (CNS) of
HAM/TAP patients [20,21]. These findings suggest that
virus-infected or activated MPs may play a role in
immune regulation and disease progression in patients
with HTLV-I-associated neurological diseases.
MPs are widely distributed immune cells that maintain
tissue homeostasis and provide a first line of defense
against invading pathogens. MPs have been shown to pre-
sent antigens bound by major histocompatibility complex
(MHC) molecules and to activate CD4+ T helper cells or
cytotoxic CD8+ T cells [22]. The abilities to combat micro-
bial infection and clear debris are intimately tied to MP
activation and follow degenerative, inflammatory, infec-
tious, and ischemic insults. However, under inflammatory
conditions, differential MP population and activation of
MPs are related to immunopathogenesis and disease pro-
gression. Human peripheral monocytes contain two major
subsets, the CD14+CD16- and CD14lowCD16+ monocytes
[23]. The CD14lowCD16+ monocytes express higher levels
of proinflammatory cytokines than CD14+CD16- mono-
cytes, with a higher capacity for antigen presentation, and
are increased in inflammatory and infectious diseases in
humans [24]. Macrophage/microglial inflammatory activ-
ities have been shown to influence a number of neurode-
generative diseases including human immunodeficiency
virus (HIV)-associated dementia, Alzheimer’s disease, Par-
kinson’s disease, stroke, brain and spinal cord trauma [25].
In HAM/TSP, the expression of proinflammatory cyto-
kines such as IL-1b, TNF-a and IFN-g is detected in per-
ipheral blood mononuclear cells (PBMCs) as well as in
perivascular infiltrating macrophages and microglia in the
spinal cords of patients with HAM/TSP [26,27]. Moreover,
HTLV-I Tax has been reported to induce the human
proIL-1b gene promoter in monocytic cells [28]. Thus,
MPs of patients with HAM/TSP might be activated under
inflammatory conditions and play a role in immunopatho-
genesis of this disorder.
In this study, we demonstrate that CD14+ cells of
patients with HAM/TSP showed an inflammatory pheno-
type as evidenced by high expression of HLA-DR and
CX3CR1, proinflammatory cytokines (TNF-a and IL-1b)
and acceleration of HTLV-I Tax expression in CD4+ T
cells. Minocycline, which is tetracycline derivative and a
known inhibitor of activated macrophage/microglia [29],
significantly inhibited TNF-a and IL-1b expressions in
cultured CD14+ cells of patients with HAM/TSP. More-
over, treatment with minocycline demonstrated inhibi-
tion of IFN-g expression in CD8+ T cells of patients with
HAM/TSP, resulting from inhibition of MP activation by
minocycline. These results demonstrate that CD8+ T cell
activation of patients with HAM/TSP can be suppressed
through down-regulation of MP activation, and suggest a
novel treatment strategy in patients with HTLV-I asso-
ciated neurological disease.
Results
High CX3CR1 and HLA-DR expression in monocytes of
patients with HAM/TSP
To characterize CD14+ cell subsets in PBMCs of HAM/
TSP patients, the expression of monocyte markers CD14
and CD16 was examined by flow cytometry in NDs,
ACs and patients with HAM/TSP. Figure 1A demon-
strates a representative dot plot of MP populations of a
ND and a patient with HAM/TSP. Group analysis did
not show significant differences between CD14+CD16-
and CD14lowCD16+ frequencies in MP population
among NDs, ACs, and patients with HAM/TSP (data
not shown). Previous reports demonstrated that
CD14lowCD16+ monocytes expressed higher levels of
CX3CR1 (a fractalkine receptor) and HLA-DR, proinflam-
matory cytokines and higher potency in antigen presenta-
tion in human inflammatory and infectious diseases
[23,24]. We therefore compared CX3CR1 and HLA-DR
expression on CD14lowCD16+ monocytes among the
groups. A representative dot plot shows that both
CX3CR1 and HLA-DR expression was higher in
CD14lowCD16+ subset of a patient with HAM/TSP than
that of a ND (Figure 1A). In NDs, the CD14lowCD16+ sub-
set expressed both CX3CR1 and HLA-DR (mean+/-stan-
dard deviation (SD) = 7.572+/-6.748, n = 10; Figure 1B). In
contrast, the CD14lowCD16+ subset of patients with
HAM/TSP had significantly higher levels of both CX3CR1
and HLA-DR expression (mean+/-SD = 51.88+/-24.42,
n = 12; Figure 1B). CX3CR1 and HLA-DR expression in
CD14lowCD16+ subset of ACs was significantly lower than
those in patients with HAM/TSP, and at comparable levels
with those in NDs (mean+/-SD = 15.04+/-13.31, n = 6;
Figure 1B). These results demonstrated that the
CD14lowCD16+ subset in patients with HAM/TSP showed
significantly high expression of CX3CR1 and HLA-DR,
compared to NDs and ACs.
Given the high expression of CX3CR1 and HLA-DR on
the CD14lowCD16+ subset in patients with HAM/TSP,
we asked whether these changes in MP subsets were
related to biomarkers of disease activity in HAM/TSP.
We previously reported that CD14+ cells induced degra-
nulation and IFN-g expression in CD8+ T cells of patients
with HAM/TSP in vitro [19]. We therefore analyzed the
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Figure 1 Characterization of mononuclear phagocytes in patients with HAM/TSP. (A) Representative dot plots of CX3CR1 and HLA-DR
expression in CD14low CD16+ cells of a ND and a HAM/TSP patient. (B) Comparison of frequencies of CX3CR1
+ HLA-DR+ cells in CD14low CD16+
mononuclear phagocytes of NDs, ACs and HAM/TSP patients. The data were obtained from ten NDs, six ACs and twelve HAM/TSP patients. The
CD14lowCD16+ subset of HAM/TSP patients had significantly higher levels of both CX3CR1 and HLA-DR expression, compared to NDs (p =
0.0001) and ACs (p = 0.0076) by Mann-Whitney test. The horizontal line represents the mean. (C) The frequency of CX3CR1
+HLA-DR+ cells was
shown to be significantly correlated with spontaneous degranulation/IFN-g expressions in CD8+ T cells of HTLV-I-infected patients, including ACs
(n = 6, opened circle) and patients with HAM/TSP (n = 12, closed circle) by simple linear regression analysis (P = 0.0004, R2 = 0.5520). (D)
Localization of CX3CR1
+ cells in the spinal cord of a HAM/TSP patient. Parenchyma (i) and meninges (ii) were stained with antibodies for CX3CR1
(brown). Parenchyma was stained with antibody for CX3CR1 (brown in iii), and double-stained with CX3CR1 and CD68 (red in iv). CX3CR1
+ cells
were positive for CD68. Magnifications, ×20. Black bar = 40 μm.
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relationship between CX3CR1/HLA-DR expression on
CD14lowCD16+ subset and degranulation/IFN-g expres-
sion in CD8+ T cells of HTLV-I-infected patients.
CX3CR1/HLA-DR expression on CD14
lowCD16+ subset
was significantly correlated with degranulation/IFN-g
expression in CD8+ T cells of HTLV-I-infected patients
(Figure 1C; P = 0.0004, R2 = 0.552). These results sug-
gested that activation of MP in vivo could be related to
CD8+ T cell activation of patients with neurologic inflam-
matory disease.
Immunohistochemical analysis further demonstrated
that CX3CR1
+ cells were detected in the spinal cord of a
patient with HAM/TSP (Figure 1D). CX3CR1
+ cells were
detected around the blood vessels and in the parenchyma
and the meninges in the HAM/TSP spinal cord (Figure
1Di and 1Dii, respectively), suggesting a recruitment of
CX3CR1
+ cells from the periphery to the spinal cord par-
enchyma and meninges. Moreover, CX3CR1
+ cells in the
parenchyma were morphologically bigger (Figure 1Diii)
and positive for CD68 (Figure 1Div), probably correspond-
ing to MPs. These results further support the idea that
CX3CR1
+ cells might be recruited from peripheral blood
to the spinal cord in patients with HAM/TSP.
CD14+ cells express TNF-a and IL-1b and increase HTLV-I
Tax expression in CD4+ T cells of patients with HAM/TSP
To further investigate MP activation in HAM/TSP
patients, we examined TNF-a and IL-1b expression in
cultured PBMCs of ND and HAM/TSP patients. After
culture of total PBMCs for 24 hours, the frequency of
CD14+ cells that expressed TNF-a was first examined by
flow cytometry. CD14+ cells expressing TNF-a was sig-
nificantly elevated in HAM/TSP patients, compared to
NDs (Figure 2A). IL-1b was detected in PBMC culture
supernatants of HAM/TSP patients but not of NDs (Fig-
ure 2B). Since relative expression of IL-1b mRNA drama-
tically increased in CD14+ cells after culture (data not
shown), IL-1b detected in the culture supernatants would
be released from the MPs of HAM/TSP patients.
In addition to the production of various proinflamma-
tory cytokines, activated or virus-infected MPs, such as
infection with HIV, effectively transfer or promote pro-
ductive virus upon interaction with T cells [30,31].
Although CD14+ cells of patients with HAM/TSP are
activated and also infected with HTLV-I at low levels, we
wished to determine if there would be an increase in
HTLV-I production in CD4+ T cells of patients with
HAM/TSP after interaction with autologous CD14+ cells.
To address whether CD14+ cells promote HTLV-I pro-
duction in CD4+ T cells of patients with HAM/TSP, we
examined HTLV-I Tax expression of CD4+CD25+ T cells
and CD4+CD25- T cells cocultured with or without auto-
logous CD14+ cells of patients with HAM/TSP,
compared to those of ACs. As shown in Figure 2Ci, in
patients with HAM/TSP, 5.8-9.5% of CD4+CD25+ T cells
expressed HTLV-I Tax proteins at baseline. After cocul-
ture with autologous CD14+ cells, HTLV-I Tax expres-
sion was dramatically increased in CD4+CD25+ T cells
(14.1-15.9%, p = 0.0226; Figure 2Ci). While HTLV-I Tax
expression was also detected in 0.8-4.4% of CD4+CD25-
T cells, an increase after coculture with CD14+ cells was
lower than in CD4+CD25+ T cells (Figure 2Cii). Since the
increase of Tax expression was not detected in CD4+ T
cells without cell-cell contact with CD14+ cells (data not
shown), the increased expression of HTLV-I Tax in
CD4+ T cells by the addition of CD14+ cells was cell-
dependent. By contrast, both CD4+CD25+ T cells and
CD4+CD25- T cells of ACs showed lower expression of
Tax proteins (< 1%), which did not change after coculture
with autologous CD14+ cells (Figure 2C). Thus, CD14+
cells could accelerate Tax expression in HTLV-I-infected
CD4+ T cells of patients with HAM/TSP.
Minocycline inhibited MP activation and spontaneous
lymphocyte proliferation of patients with HAM/TSP
Since various therapeutic agents have been developed
for neuroinflammatory diseases specifically aimed at the
inhibition of activated MPs, we attempted to examine
the inhibition of MP function in patients with HAM/
TSP using minocycline, which is known as an inhibitor
of monocyte/macrophage activation. To evaluate inhibi-
tory effect of minocycline on activated MP of patients
with HAM/TSP, we examined TNF-a expression in cul-
tured PBMCs of patients with HAM/TSP by treatment
with minocycline. As shown in Figure 3A, the frequency
of CD14+ cells expressing TNF-a was significantly
inhibited at 10 μM of minocycline treatment in HAM/
TSP patients (Figure 3A; closed bar, p = 0.0313). The
cultured CD4+ T cells also expressed TNF-a, but mino-
cycline did not inhibit TNF-a expression in CD4+ T
cells (Figure 3A; opened bar). As demonstrated pre-
viously (Figure 2B), IL-1b was detected in the superna-
tants of cultured PBMCs of patients with HAM/TSP;
the release of IL-1b from these cultured HAM/TSP
PBMCs was also inhibited by 10 μM of minocycline
treatment (p = 0.0078; Figure 3B). These results demon-
strated that minocycline inhibited the expression of
proinflammatory cytokines from MPs, but not from
CD4+ T cells, of patients with HAM/TSP.
An additional established measure of HAM/TSP T cell
activation ex vivo is the well-described observations of
increased spontaneous lymphoproliferation [5]. In addi-
tion to the expression of HTLV-I Tax and a variety of
cytokines in PBMCs of HTLV-I-infected patients that are
associated with spontaneous lymphoproliferation [32-34],
the activation of MP is also involved in spontaneous
Enose-Akahata et al. Retrovirology 2012, 9:16
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lymphoproliferation of patients with HAM/TSP [5]. To
address the inhibitory effects of minocycline on sponta-
neous lymphoproliferation, uptake of [3H] thymidine as a
marker of proliferation was examined in PBMCs of two
patients with HAM/TSP after treatment with minocy-
cline. In minocycline-treated HAM/TSP PBMCs, the
spontaneous lymphoproliferation was inhibited in a dose-
dependent manner (Figure 3C). Since the treatment with
minocycline did not inhibit HTLV-I Tax expression in
both T cells and CD14+ cells (data not shown), these
results showed that minocycline can downregulate MP
activation, such as proinflammatory cytokine expression.
Minocycline inhibits spontaneous degranulation and IFN-g
expression in CD8+ T cell of patients with HAM/TSP
MPs play an indispensable role in the induction of anti-
gen-specific CTL responses by capturing viral antigen and
presenting peptide through MHC class I to CD8+ T cells.
In patients with HAM/TSP, HTLV-I-infected or activated
MPs collaborate with CD8+ T cell to induce spontaneous
degranulation and high IFN-g expression [19]. Since we
have demonstrated that minocycline has inhibitory effects
on activated MPs (Figure 3), minocycline might also inhi-
bit MP function such as triggering adaptive immune
responses. To determine if inhibition of MPs affects CD8+
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Figure 2 Activated CD14+ cells in patients with HAM/TSP. (A) TNF-a expression in CD14+ cells of NDs and HAM/TSP patients after culture for
24 hours. The data were obtained from six NDs and six HAM/TSP patients. CD14+ cells expressing TNF-a was significantly elevated in HAM/TSP
patients, compared to NDs by Mann-Whitney test (p = 0.0022). The horizontal line represents the mean. (B) Detection of IL-1b in PBMC culture
supernatants of NDs and HAM/TSP patients after culture for 24 hours. The data were obtained from five NDs and eight HAM/TSP patients. IL-1b
expression in HAM/TSP patients was significantly higher in those cells of NDs by Mann-Whitney test (p = 0.0043). The horizontal line represents
the mean. (C) Tax expressions in CD4+CD25+ T cells (i) and CD4+CD25- T cells (ii) cocultured with or without autologous CD14+ cells of ACs (n =
2, opened circle) and patients with HAM/TSP (n = 3, closed circle) for 18 hours.
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T cell responses in HAM/TSP, we examined the effect of
minocycline on expression of CD107a, a marker of degra-
nulation, and IFN-g in CD8+ T cells of patients with
HAM/TSP. As previously reported [19], CD107a and IFN-
g were spontaneously expressed in CD8+ T cells of a
patient with HAM/TSP after PBMC culture for 24 hours
without any exogenous stimuli, but not in those cells of a
ND. In Figure 4A, representative dot plots show that treat-
ment with minocycline inhibited CD107a and IFN-g
expression in CD8+ T cells of a patient with HAM/TSP.
Group analysis showed significant, dose-dependent,
inhibitory effects of minocycline on spontaneous degranu-
lation and IFN-g expression in CD8+ T cells of patients
with HAM/TSP (Figure 4B). These results demonstrated
that spontaneous degranulation and IFN-g expression in
CD8+ T cells of patients with HAM/TSP were inhibited by
treatment with minocycline.
Minocycline inhibits antigen-specific CD8+ T cells
responses in patients with HAM/TSP
To confirm whether treatment with minocycline could
inhibit antigen-specific CD8+ T cell responses of
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Figure 3 Minocycline inhibited TNF-a expression and IL-1b release in patients with HAM/TSP. (A) Dose-dependent inhibitory effects of
minocycline on TNF-a expressions in CD14+ cells (closed bar) and CD4+ T cells (opened bar) of HAM/TSP patients (n = 6). The PBMCs were
cultured with 0, 5 and 10 μM of minocycline for 24 hours. The frequency of CD14+ cells expressing TNF-a was significantly inhibited at 10 μM of
minocycline treatment in HAM/TSP patients (p = 0.0313; Wilcoxon matched-pairs signed rank test). Error bars represent SD. (B) Inhibition of IL-1b
release in PBMC culture supernatants of HAM/TSP patients by 10 μM of minocycline after culture for 24 hours (n = 8). The release of IL-1b from
these cultured HAM/TSP PBMCs was significantly inhibited by minocycline treatment (p = 0.0078; Wilcoxon matched-pairs signed rank test). (C)
Inhibitory effects of minocycline on spontaneous lymphoproliferation in HAM/TSP patients. The PBMCs from two HAM/TSP patients (HAM#1 and
#2) were cultured with 0, 2.5, 5 and 10 μM of minocycline, and pulsed with 1 μCi [3H] thymidine for 4 hours at 3 days (closed circle), 4 days
(closed square) and 5 days (closed triangle). The average cpm from each well in triplicate was plotted.
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Figure 4 Minocycline inhibited spontaneous degranulation/IFN-g expression in CD8+ T cells of patients with HAM/TSP. (A)
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patients with HAM/TSP, we examined CD107a and
IFN-g expression in CD8+ T cells of patients with
HAM/TSP, who were subtyped as HLA-A*201, by sti-
mulation with a known immunodominant HLA-A2-
binding HTLV-I Tax11-19 peptide [35]. As previously
reported [36], cytotoxicity (CD107 expression) can be
triggered at peptide concentrations 10- to 100-fold less
than those required for inflammatory cytokine (IFN-g)
production in primary virus-specific human CD8+ T
cells. In CD8+ T cells of a patient with HAM/TSP, after
stimulation with the low peptide concentration (0.1 ng/
ml) for 5 hours, the majority of responding cells degra-
nulated, but produced little or no detectable IFN-g (Fig-
ure 5A). As the peptide concentration was increased,
more cells exhibited dual effector functions of degranu-
lation and IFN-g production (Figure 5A). Thus, CD8+ T
cells exhibited inflammatory changes following cytotoxic
responses depending on the quantity of antigen stimula-
tion. Figure 5B shows representative dot plots of
CD107a and IFN-g expressions in CD8+ T cells of a
HLA-A*201+ patient with HAM/TSP after the Tax11-19
stimulation with or without minocycline treatment. As
the peptide concentration increased, more cells exhib-
ited both degranulation and IFN-g production in CD8+
T cells of a HAM/TSP patient (Figure 5B, upper dot
plots). Interestingly, as the cells were treated with minocy-
cline, both degranulation and IFN-g production were
detected in Tax11-19-specific CD8+ T cells, but the fre-
quency of CD107a+IFN-g+ cell population did not increase
in CD8+ T cells stimulated with increased Tax11-19 pep-
tides (Figure 5B, lower dot plots). These results suggested
that minocycline inhibited the activation of Tax-specific
CD8+ T cells (Figure 5B, lower dot plots). In addition,
IFN-g expression was reduced, but total CD107a expres-
sion did not change in Tax11-19-specific CD8+ T cells
after minocycline treatment (Figure 5B, lower dot plots).
Three HLA-A*201+ HAM/TSP patients showed that min-
ocycline treatment inhibited 40% of CD107a+IFN-g+
expressions, but not total CD107a expressions, in CD8+ T
cells after stimulation with Tax11-19 (Figure 5C). These
results demonstrated that treatment with minocycline
reduced the inflammatory responses (IFN-g expression),
but retained anti-viral cytotoxic response (total CD107a
expression) in Tax11-19-specific CD8+ T cells of HAM/
TSP patients.
Minocycline down-regulated MHC class I expression on
MPs of patients with HAM/TSP
As CD8+ T cells are stimulated by antigenic peptides that
are presented by MHC class I molecules expressed on the
surface of antigen-presenting cells, we asked whether the
effect of minocycline that modulates the inflammatory
response in Tax-specific CD8+ T cells of patients with
HAM/TSP might be associated with decreased capacity of
antigen-presentation in MPs. To clarify the capacity of
antigen-presentation in MPs, we examined MHC class I
expression on MPs of patients with HAM/TSP after cul-
ture with or without minocycline treatment. Figure 6A
shows representative histograms of MHC class I expres-
sion on CD14+ cells in a patient with HAM/TSP before
and after culture for 5 and 18 hours. MHC class I expres-
sion on CD14+ cells of a patient with HAM/TSP gradually
increased after culture (Figure 6A). After treatment with
minocycline, MHC class I expression on CD14+ cells gra-
dually decreased, compared to those on CD14+ cells with-
out minocycline (Figure 6A). Group analysis including
three patients with HAM/TSP showed that mean fluores-
cent intensities of MHC class I expression on CD14+ cells
were significantly inhibited by treatment with minocycline
after 18 hours culture (Figure 6B). These results demon-
strated that minocycline down-modulated MHC class I
expression on activated HAM/TSP MPs, suggesting that
the inflammatory response of CD8+ T cells in patients
with HAM/TSP was suppressed through down-regulation
of MP activation by minocycline.
Discussion
MPs play pivotal roles in antigen capture and presentation,
pathogen and tissue debris clearance, and cellular secre-
tory functions. However, activated MPs can infiltrate
through the blood brain barrier and contribute to the CNS
inflammation by secreting various inflammatory cytokines
and growth-inhibiting proteins. In HAM/TSP, MPs are
reservoirs of HTLV-I, induce proinflammatory cytokines
and excessive antigen-specific T cell responses, and can
also infiltrate the CNS. In our study, we analyzed CD14+
cell subpopulation in PBMCs of patients with HAM/TSP
and demonstrated that CD14lowCD16+ subset of patients
with HAM/TSP showed significantly higher CX3CR1 and
HLA-DR expression, compared to NDs and ACs. Since it
has been reported that CX3CR1 expression is regulated by
IL-2 and IL-15 [37], activated T cells expressing these
cytokines might affect CX3CR1 expression on monocytes
in patients with HAM/TSP [19,38,39]. In mice, GR1-
CX3CR1
high monocytes (homolog of human CD16+ mono-
cytes) patrol vascular endothelium by mechanisms invol-
ving LFA-1 and CX3CR1 and are rapidly recruited into
inflamed tissues, such as spleen, gut, lung and brain,
where they differentiate into macrophage [23,40]. In
humans, CD16+ monocytes that have the potential to
migrate preferentially in response to fractalkine, a ligand
of CX3CR1, have more Fc receptor mediated phagocytosis
function and are at a more advanced stage of differentia-
tion to macrophage and dendritic cell [41-43]. These find-
ings suggest that CD14lowCD16+ and CD14+CD16- cells
are recruited into different anatomic sites under constitu-
tive or inflammatory conditions and play distinct func-
tional roles in immunity and disease pathogenesis.
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Figure 5 Minocycline inhibited Tax11-19-specific IFN-g expression in CD8+ T cells of patients with HAM/TSP. (A) Representative dot plots
of CD107 and IFN-g expression in CD8+ T cells of a HLA-A*201+ HAM/TSP patients, stimulated with Tax11-19 peptides. PBMCs were stimulated
with Tax 11-19 peptide at concentration of 0, 0.1, 1, 10, 100 ng/ml, and 1 μg/ml for 5 hours. (B) Representative dot plots of Tax11-19 specific
CD107 and IFN-g expression in CD8+ T cells of a HAM/TSP patient after treatment with or without 10 μM of minocycline. PBMCs were stimulated
with Tax 11-19 peptide at concentration of 0, 10 ng/ml and 1 μg/ml for 5 hours. (C) Inhibitory effects of minocycline on IFN-g expression, but
not degranulation, in CD8+ T cells of HAM/TSP patients after stimulation with 1 μg/ml of Tax11-19 peptides. The amounts of CD107a+ (closed
circles) and CD107a+IFN-g+ (opened circles) cells in CD8+ T cells cultured without minocycline were normalized to 100%, and then, those in CD8
+ T cells cultured with minocycline were calculated. The graph was prepared from data obtained from three HLA-A*201+ HAM/TSP patients.
Tax11-19-specific IFN-g expression, but not degranulation, in CD8+ T cells of HAM/TSP patients was inhibited 40% by minocycline treatment.
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Fractalkine is expressed on activated endothelial cells [44],
neuron [45], apoptotic cells [46], and brain with inflamma-
tion [47]. Therefore, HTLV-I-activated or infected cells
might induce fractalkine expression at the site of inflam-
mation such as the spinal cord to recruit and adhere
CX3CR1
+ cells. The hypothesis was supported by the
accumulation of CX3CR1
+ cells immunohistochemically
detected in the meninges and parenchyma of HAM/TSP
spinal cords as well as around blood vessels (Figure 1D).
The CX3CR1
+ cells were CD68+ and also morphologically
consistent with MPs. Therefore, these results suggested
that CX3CR1
+ MPs could accumulate in spinal cords of
patients with HAM/TSP. Moreover, the increase of degra-
nulation and IFN-g expression in CD8+ T cells were signif-
icantly correlated with the increase of CX3CR1 and HLA-
DR expression in CD14lowCD16+ subset of HTLV-I-
infected patients. These results support the hypothesis
that strong correlation between CD8+ T cell activation
and MP activation contribute to the pathogenesis of
HAM/TSP. These differential changes in peripheral MP
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Figure 6 Minocycline downregulated HLA-ABC expressions in CD14+ cells of patients with HAM/TSP. (A) Representative histograms of
HLA-ABC expression on CD14+ cells of a HAM/TSP patient. Staining on CD14+ cells before culture (closed histogram) and after culture for 5
hours and 18 hours, with minocycline (grayed histogram) and without minocycline (opened histogram), were shown. (B) Comparison of HLA-
ABC expression in CD14+ cells of HAM/TSP patients after 18 hours culture with minocycline (closed circle) or without minocycline (opened
circle). The mean fluorescent intensities of MHC class I expression on CD14+ cells were significantly inhibited by treatment with minocycline at
18 hours culture (*p = 0.0382). Error bars represent SD.
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subpopulations in vivo may also be associated with the
infiltration of MPs into the CNS and CD8+ T cell activa-
tion in patients with neurologic inflammatory disease.
MP activation in patients with HAM/TSP was also
suggested by TNF-a and IL-1b expression in CD14+
cells. Expression of IL-1b and TNF-a was detected in
perivascular infiltrating macrophages and microglia in
the spinal cords of patients with HAM/TSP and in infil-
trating macrophage in the muscle of patients with
HTLV-I-related myositis [27,48]. Thus, the proinflam-
matory cytokine expression in peripheral MPs might be
related to the infiltration of MPs into the inflammatory
site of patients with HTLV-I-related diseases. Moreover,
CD14+ cells accelerated HTLV-I Tax expression of auto-
logous CD4+CD25+ T cells in patients with HAM/TSP,
which was dependent on cell-cell contact. In patients
with HAM/TSP, high HTLV-I Tax expression is mainly
detected in CD4+ T cells after ex vivo culture, but den-
dritic cells and CD14+ cells can also express HTLV-I
Tax, consistent with the observation that HTLV-I
infects dendritic cells to effectively transfer cell-free
virus to CD4+ T cells [18,19]. In HIV, human CD16+
monocytes have been shown to be more susceptible to
infection than CD16- monocytes, to preferentially harbor
the virus over the long-term, and to promote high levels
of HIV replication upon differentiation into macro-
phages and interaction with activated T cells [30,49].
Therefore, HTLV-I infected and activated MP might
likewise contribute to T cell activation and virus disse-
mination in HTLV-I associated disease.
Minocycline is a well known as inhibitor of MP activa-
tion and has been reported to have beneficial effects on
inflammation, microglial activation, matrix metalloprotei-
nases, nitric oxide production, and apoptotic cell death
[29]. Furthermore, minocycline has been suggested to
have neuroprotective effects in human as well as in ani-
mal models of a number of neurologic diseases including
stroke, multiple sclerosis, and Parkinson’s disease [29]. In
our study, minocycline treatment significantly inhibited
proinflammatory cytokine expression (TNF-a and IL-1b)
in CD14+ cells of patients with HAM/TSP, while TNF-a
expressions in CD4+ T cells of patients with HAM/TSP
did not change. These results suggest that the effects of
minocycline may act through inhibition of MP activation
rather than HTLV-associated T cell activation. Unexpect-
edly, minocycline treatment also effectively inhibited
spontaneous lymphoproliferation and IFN-g expression
of CD8+ T cells, which are well-described observations of
T cell activation in patients with HAM/TSP. While these
T cell responses have been reported to be due to IL-2/IL-
2 receptor and IL-15/IL-15 receptor autocrine loop fol-
lowing expression of HTLV-I Tax in T cells [32,38], a
number of studies have demonstrated that non-T cells
and CD14+ cells can also play a stimulatory role in
HTLV-I-associated T cell activation [5,19,38]. Therefore,
our results support the view that T cell responses in
patients with HAM/TSP are due, in part, to the activation
of MPs.
Inhibition of MPs resulted in the suppression of CD8+ T
cell dysregulation (degranulation and IFN-g expression).
Elevated IFN-g expression is an important immunological
marker in the pathogenesis of HAM/TSP [50], and CD8+
T cell dysregulation was mediated by various factors,
including virus infection, enhanced IL-2/IL-15, and
expression of cellular molecules [19,51-54]. Unexpectedly,
minocycline inhibited spontaneous degranulation/IFN-g
expression in CD8+ T cells of HAM/TSP patients as well
as HTLV-I Tax11-19-specific CD8+ T cell responses. Anti-
viral CD8+ T cells can elaborate at least two effector func-
tions, cytotoxicity and inflammatory cytokine production,
which are determined primarily by antigen concentration
[36]. Interestingly, minocycline treatment suppressed
inflammatory IFN-g production, but not total cytotoxicity
(CD107a expression) in Tax-specific CD8+ T cells of
patients with HAM/TSP. Moreover, after the treatment
with minocycline, MHC class I expression on CD14+ cells
of patients with HAM/TSP was gradually suppressed in
cultured cells, compared to untreated MPs. These results
suggested that the activation of CD8+ T cells was inhibited
through MHC class I downregulation on CD14+ cells after
minocycline treatment. This may be one mechanism
involved in the reduction of CD8+ T cell inflammatory
IFN-g production in the presence of minocycline. More-
over, minocycline significantly inhibited spontaneous
degranulation/IFN-g expression in CD8+ T cells of HAM/
TSP patients. As previously reported, the spontaneous
degranulation/IFN-g expression in CD8+ T cells of HAM/
TSP patients was mediated by various factor(s) [19,52]. To
evaluate regulatory effects of CD8+ T cell by minocycline,
further analysis would be needed. In addition, even though
minocycline down-modulates the capacity of antigen-pre-
senting cells to trigger CD8+ T cell effector responses, the
cytotoxic function of Tax-specific CD8+ T cells might
be still maintained and continue to provide control of
virus-infected cells. This may have a positive clinical con-
sequence for use of minocycline in treatment of HTLV-I-
associated disease.
Conclusions
Collectively, these results suggest that minocycline does
not only inhibit the activation of MPs of patients with
HAM/TSP, but also HTLV-I-associated T cell activa-
tion such as lymphoproliferation and inflammatory
cytokine production of CD8+ T cells through the
downregulation of MP function. Thus, the inhibition of
HTLV-I-infected or activated MPs may be of clinical
use in the treatment of patients with HTLV-I-asso-
ciated neurological disease.
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Methods
Patient samples
Blood samples were obtained from twelve patients with
HAM/TSP (HAM#1-12), six HTLV-I-seropositive asymp-
tomatic carriers (AC#1-6), and ten HTLV-I-seronegative
healthy donors (ND#1-10). Diagnosis of HAM/TSP was
based on WHO diagnostic criteria. Three patients with
HAM/TSP were HLA-A*201+. PBMCs were isolated by
Ficoll-Hypaque (Lonza Walkersville, Walkersville, MD)
centrifugation. The PBMCs obtained from HTLV-I-
infected patients or ND were cryopreserved in liquid
nitrogen until use. Informed consent was obtained from
each subject. The study was reviewed and approved by the
National Institute of Neurological Disorders and Stroke
(NINDS) Institutional Review Board. Informed consent
was obtained in accordance with the Declaration of
Helsinki.
Antibodies and reagents
For flow cytometry, antibodies for human CD3, CD4,
CD8, CD14, CD16, CD28, CD49d, CD107a, IFN-g, TNF-
a, and HLA-DR (all from BD Biosciences, San Jose, CA),
CX3CR1 (Medical and Biological laboratories, Nagoya,
Japan), HLA-ABC (AbD Serotec, Oxford, UK), and anti-
Tax monoclonal antibody (Lt-4) were used. For immuno-
histochemistry, rabbit polyclonal anti-human CX3CR1
(abcam, Cambridge, MA) was used as primary antibody.
Minocycline was purchased from Sigma (St. Louis, MO).
Cell culture
PBMCs of NDs or patients with HAM/TSP were sus-
pended at 1 × 106 cells/mL in RPMI media (RPMI 1640
supplemented with 10% heat-inactivated fetal bovine
serum, 100 U/mL penicillin, 100 μg/mL streptomycin sul-
fate, and 2 mM L-glutamine), and cultured for 24 hours
either with or without minocycline in 24 well plate in 5%
CO2 incubator at 37°C. The culture supernatants were col-
lected, centrifuged at 2000 g for 10 min to remove cellular
debris and stored at -80°C until use. The cultured cells
were collected for immunofluorescence staining or stored
at -80°C until use. For immunofluorescence staining of
MHC class I on MPs, PBMCs were collected after culture
for 5 hours or 18 hours.
To examine Tax expression in CD4+ T cells cocultured
with or without CD14+ cells, CD4+CD25+ T cells or CD4
+CD25- T cells and CD14+ cells were magnetically isolated
from PBMCs of HTLV-I-infected patients by CD4+CD25+
Regulatory T cell Isolation Kit and CD14 MicroBeads
(both from Miltenyi Biotec, Bergisch Gladbach, Germany),
respectively, according to the manufacture’s instruction,
and 2 × 105 cells of each CD4+ T cells were cocultured
with or without the same amount of autologous CD14+
cells for 18 hours in 48 well plate in 5% CO2 incubator at
37°C.
ELISA
IL-1b was detected in the PBMC culture supernatants of
NDs and patients with HAM/TSP using Human IL-1b
Quantikine ELISA (R & D systems), according to the
manufacturer’s instructions
CD107a mobilization assay
CD107a mobilization assay was performed as previously
described [19]. To detect spontaneous degranulation
and IFN-g expression in CD8+ T cells, PBMCs of
patients with HAM/TSP were cultured for 24 hours. To
detect Tax11-19 specific responses, PBMCs were stimu-
lated with an appropriate concentration of HTLV-I
Tax11-19 LLFGYPVYV and 1 μg/mL each of CD28 and
CD49d for 5 hours. In treatment of minocycline, appro-
priate minocycline was added into the culture. Conju-
gated CD107a antibody, 0.7 μL/mL of GoldiStop™ (BD
Biosciences), and 1 μg/mL of brefeldin A (Sigma) were
added into the culture for 5 hours before the time point
for detection.
Flow cytometry
For analysis of peripheral blood monocyte populations,
patients’ PBMCs were stained with CD3, CD4, CD8,
CD14, CD16, HLA-DR and CX3CR1. Expression of
CD107a, IFN-g, TNF-a and intracellular Tax in the cul-
tured or uncultured PBMCs was examined by flow cyto-
metoric analysis. First, PBMCs were surface-stained with
specific antibodies. After fixation and permeabilization
with Fixation/Permeabilization solution (BD Biosciences)
according to the manufacturer’s instructions, the cells
were intracellularly stained with anti-IFN-g, anti-TNF-a
or anti-Tax for each experiment. Flow cytometric analy-
sis was performed using a FACSCalibur flow cytometer
(BD Biosciences) or LSR II (BD Biosciences). The data
were analyzed using FlowJo software (Tree Star, San
Carlos, CA).
Lymphoproliferation assay
Lymphoproliferation assay was performed as previously
described [55]. PBMCs were suspended in RPMI med-
ium supplemented with 5% human AB serum, 100 U/
mL penicillin, 100 μg/mL streptomycin sulfate, and 2
mM L-glutamine, and plated in triplicate on a round
bottom 96-well plate at a concentration of 3 × 105 cells/
well with or without minocycline. The cells were cul-
tured in 5% CO2 incubator at 37°C, and pulsed after 3
to 5 days of culture for 4 h with 1 μCi [3H] thymidine.
The average cpm from each of the wells was plotted.
Immunohistochemistry
Spinal cord tissues from a patient with HAM/TSP were
fixed with buffered formalin and embedded in paraffin
wax. Microtome sections were cut 10 μm thick. Sections
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were deparaffinized with xylene, rehydrated and
immersed in Target Retrieval Solution, pH6.0, (Dako,
Carpinteria, CA) at 121°C for 10 min. After blocking of
endogenous peroxide with 3% hydrogen peroxide for 10
min, the sections were incubated with a rabbit anti-
CX3CR1 antibody (1 μg/ml) for one hour at room tem-
perature. Reactivity was visualized with diaminobenzi-
dine (DAB) using Envision™+system (Dako), followed
by counterstaining with hematoxylin. The stained sec-
tions were visualized with Zeiss 200M Axiovert inverted
microscope (Carl Zeiss MicroImaging Inc, Thornwood,
NY). The image data of each section were created using
Volocity imaging analysis software (Improvision, Wal-
tham, MA).
Statistical analysis
Mann-Whitney test and Wilcoxon matched-pairs signed
rank test were used for comparison between groups.
Simple linear regression analysis was used for explaining
a relationship between groups, respectively. All statistical
analysis was performed using Prism (GraphPad
software).
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